Glenmark to divest select brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan

30 Nov 2020 Evaluate

Glenmark Pharmaceuticals has entered into a definitive agreement with Dr. Reddy’s Laboratories to divest - subject to completion of certain precedent actions and closing activities - its brand Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along with rights to the trademarks, dossiers and patents for the territories mentioned.

The divested brand and its extensions represent two types of products, i.e Mometasone mono product and combination of Mometasone with Azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

954.95 -8.05 (-0.84%)
28-Mar-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.